NIDA supports development of combined anti-heroin and HIV vaccine

July 25th, 2012
This is a diagram of the heroin vaccine portion of the heroin-HIV vaccine. The heroin-haptens are attached to tetanus toxoid mixed with liposomes containing phosphoryl lipid A, which is potent adjuvant formulation used to induce high titer antibodies to heroin. Credit: Image courtesy Dr. Gary R. Matyas
Dr. Gary R. Matyas has been selected the 2012 recipient of the NIDA Avant-Garde Award for Medications Development. Matyas proposes to develop an effective, safe and easily manufactured combination anti-heroin/HIV vaccine that could treat heroin addiction while at the same time prevent HIV infection in those receiving the vaccine. Matyas will receive $1,000,000 per year for five years to support his research. He works at the Walter Reed Army Institute of Research (WRAIR) in Silver Spring, M.d. The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, announced the award today.

"This highly innovative dual-vaccine model would simultaneously address the intertwined epidemics of heroin abuse and HIV," said NIDA Director Dr. Nora D. Volkow. "This is precisely the type of ground-breaking research NIDA's Avant-Garde program was designed to support. The implications for public health are enormous."

The proposal stems from an existing research collaboration between NIDA and the U.S. Military HIV Research Program, part of the WRAIR. In 2010, the two organizations entered into an agreement to create a combination anti-heroin/HIV vaccine. The goal was to build upon previous preclinical research indicating that hapten-based anti-drug vaccines—in which a small molecule chemically similar to a drug of abuse (hapten) is bound to a protein carrier to induce an immune response—showed promise against a variety of abused drugs, including heroin. As a result of this collaboration, the heroin component of a combination anti-heroin/HIV vaccine has now been created and is ready for optimization and advanced preclinical testing.

This current grant award will support this next phase of research and development. The award will be administered through the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. and work done in collaboration with the U.S. Military HIV Research Program and NIDA.

"Heroin use is strongly associated with a high risk of HIV infection and represents an increasingly important worldwide health problem," stated Matyas. "The possibility of creating a combination heroin-HIV vaccine provides an important opportunity to address both a unique treatment for heroin abuse as well as continuing the quest to develop an effective preventive HIV vaccine."

Provided by National Institutes of Health

This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.

More news stories

Weighing gas with sound and microwaves

NIST scientists have developed a novel method to rapidly and accurately calibrate gas flow meters, such as those used to measure natural gas flowing in pipelines, by applying a fundamental physical principle: ...

Hybrid memory device for superconducting computing

A team of NIST scientists has devised and demonstrated a novel nanoscale memory technology for superconducting computing that could hasten the advent of an urgently awaited, low-energy alternative to power-hungry conventional ...

Helicopter could be 'scout' for Mars rovers

Getting around on Mars is tricky business. Each NASA rover has delivered a wealth of information about the history and composition of the Red Planet, but a rover's vision is limited by the view of onboard ...

Chemists find a way to unboil eggs

UC Irvine and Australian chemists have figured out how to unboil egg whites – an innovation that could dramatically reduce costs for cancer treatments, food production and other segments of the $160 billion ...